Abstract
Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Small Cell / drug therapy*
-
Cisplatin / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Granulocyte Colony-Stimulating Factor / administration & dosage*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Survival Analysis
-
Vincristine / administration & dosage
Substances
-
Granulocyte Colony-Stimulating Factor
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cisplatin